Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 33.7% in February

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 748,700 shares, a decrease of 33.7% from the February 13th total of 1,130,000 shares. Based on an average trading volume of 56,200 shares, the short-interest ratio is presently 13.3 days. Approximately 3.5% of the shares of the stock are sold short.

Acrivon Therapeutics Trading Up 7.3 %

NASDAQ:ACRV opened at $5.44 on Friday. The firm has a market capitalization of $169.38 million, a price-to-earnings ratio of -2.01 and a beta of 0.85. The business’s fifty day moving average price is $5.62 and its 200 day moving average price is $6.82. Acrivon Therapeutics has a 1-year low of $4.69 and a 1-year high of $11.90.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. KeyCorp initiated coverage on Acrivon Therapeutics in a research report on Friday, January 31st. They set an “overweight” rating on the stock. Cantor Fitzgerald initiated coverage on Acrivon Therapeutics in a report on Friday, January 31st. They set an “overweight” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.67.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRV. Barclays PLC lifted its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock worth $233,000 after buying an additional 11,273 shares during the period. State Street Corp raised its stake in Acrivon Therapeutics by 26.4% during the third quarter. State Street Corp now owns 225,896 shares of the company’s stock worth $1,581,000 after acquiring an additional 47,233 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Acrivon Therapeutics by 548.3% during the third quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after acquiring an additional 28,748 shares during the period. Exome Asset Management LLC acquired a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at $817,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Acrivon Therapeutics in the 4th quarter worth about $40,000. 71.62% of the stock is owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.